Greg Yap

Greg Yap is currently a Board Member at Delfi Diagnostics, and previously held the position of Senior Director, Marketing and Product Strategy, Urology at Exact Sciences from November 2019 to June 2020. Prior to that, they were the Director, Marketing, US Urology at Genomic Health from January 2013 to February 2020.

During their time at Genomic Health, Greg was responsible for leading the US Urology Marketing team for Oncotype DX Genomic Prostate Score (Urologist audience) and Oncotype DX AR-V7 Nucleus Detect (Urologist and Oncologist audience). Greg was also the franchise lead, responsible for cross functional alignment and partnership between Marketing, Sales, Managed Care, Medical Affairs, Product Lifecycle, Legal, Compliance, Corporate Communications, Patient Advocacy, Commercial Services, Sales Operations, and Commercial Learning. In addition, Greg was responsible for identifying, planning, and developing opportunities in urology and other potential customer markets.

After a company reorganization, Greg redeveloped the marketing team, quadrupling its size and adding new roles and structure. Greg also developed a three-year cross functional commercial strategic plan, brand plan, and tactical and operating plan. Greg provided insight on drivers, barriers, and opportunities to establish assay and revenue forecast. Greg was also accountable for the development and iteration of the near-term forecast for assay and revenue figures, as well as three-year product forecast.

Greg Yap completed a Master's in Business Administration from Santa Clara University's Leavey School of Business, as well as a Bachelor of Science in Chemistry from California State University, Chico. Greg also attended UC Berkeley Extension.